Innovent Biologics Gains FDA Approval for New Drug IBI3032, Targeting Metabolic Disorders Innovent Biologics has received FDA approval for its investigational drug IBI3032, a novel oral GLP-1R agonist aimed at treating metabolic diseases. The clinical trials will begin soon.

Innovent Biologics Gains FDA Approval for New Drug IBI3032, Targeting Metabolic Disorders #United_States #FDA_Approval #San_Francisco #Innovent_Biologics #IBI3032